BioCryst to Report Second Quarter 2025 Financial Results on August 4

Core Viewpoint - BioCryst Pharmaceuticals, Inc. will report its second quarter 2025 financial results on August 4, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of individuals with hereditary angioedema and other rare diseases [3]. - The company specializes in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics targeting difficult-to-treat diseases [3]. - BioCryst has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies [3]. Conference Call Details - The conference call will take place at 8:30 a.m. ET on August 4, 2025, and will be accessible via phone and webcast [1][2]. - Domestic callers can dial 1-844-481-2942, while international callers can reach the call at 1-412-317-1866 [2]. - A live webcast and replay will be available in the investors section of the company website [2].